Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12
Partnerships 13
OSE Immunotherapeutics Enters into Agreement with GERCOR 13
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14
Selexis Enters into Agreement with OSE Immunotherapeutics 15
OSE Pharma Partners with Effimune 16
Merger 17
Effimune and OSE Pharma Merge 17
Licensing Agreements 18
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23
OSE Pharma Enters into Licensing Agreement with RAFA Labs 24
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25
Equity Offering 26
OSE Pharma Raises USD23 Million in IPO 26
Acquisition 27
OSE Pharma Acquires OPI, Pharma Company 27
OSE Immunotherapeutics – Key Competitors 28
OSE Immunotherapeutics – Key Employees 29
OSE Immunotherapeutics – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 06, 2018: OSE Immunotherapeutics announces first-half 2018 financial results 31
Mar 28, 2018: OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products 33
Sep 07, 2017: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio 35
Corporate Communications 37
Apr 12, 2018: OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management 37
Jan 03, 2018: OSE Immunotherapeutics Announces Appointment of Gerard Tardy as Chairman of Company’s Board of Directors 39
Legal and Regulatory 40
Apr 23, 2018: OSE Immunotherapeutics Receives the Euronext Tech40 Label 40
Product News 41
12/14/2017: OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministeriel” to Explore New Cytotoxic Antibodies 41
Clinical Trials 42
May 07, 2018: OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas 42
Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases 43
Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127 44
Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference 45
Other Significant Developments 46
Jun 13, 2018: OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 9
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12
OSE Immunotherapeutics Enters into Agreement with GERCOR 13
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14
Selexis Enters into Agreement with OSE Immunotherapeutics 15
OSE Pharma Partners with Effimune 16
Effimune and OSE Pharma Merge 17
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23
OSE Pharma Enters into Licensing Agreement with RAFA Labs 24
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25
OSE Pharma Raises USD23 Million in IPO 26
OSE Pharma Acquires OPI, Pharma Company 27
OSE Immunotherapeutics, Key Competitors 28
OSE Immunotherapeutics, Key Employees 29
OSE Immunotherapeutics, Other Locations 30
OSE Immunotherapeutics, Subsidiaries 30
List of Figures
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9